AMIGO2

Across TCGA pan-cancer cohorts, AMIGO2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AMIGO2 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher AMIGO2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AMIGO2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

COAD, UCEC, and SARC are the cancer types where AMIGO2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	II,III,IV	0.117	0.792	<.001	9	view →
UCEC	DFS	Median	All	0.949	0.621	.024	8	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
BLCA	DFS	Median	All	1.000	0.329	.028	6	view →
SKCM	OS	Median	IV	0.179	0.755	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

AMIGO2–COAD (OS)

Open the COAD breakdown →